Table 1 Cytokine levels in cell lysates after 3 days of treatment.

From: Peptide-mediated delivery of donor mitochondria improves mitochondrial function and cell viability in human cybrid cells with the MELAS A3243G mutation

Cytokines (pg/ml)

Control

MELAS

Pep-1-Mito

Pep-1

Mito

IL-1β

11.5 ± 0.35

15.1 ± 1.06*

22.6 ± 1.49&

17.6 ± 1.42

29.9 ± 2.89&+

IL-8

566.8 ± 18.46

558.6 ± 32.23

795.8 ± 74.34&

469.3 ± 14.84&

858.8 ± 0.42&+

IL-7

34.4 ± 2.63

60.4 ± 1.04*

54.7 ± 2.07&

63.9 ± 5.52

66.2 ± 4.80+

IL-12(p70)

110.0 ± 5.06

26.4 ± 4.19*

37.6 ± 5.85&

33.8 ± 14.76

46.9 ± 8.85&+

GM-CSF

666.3 ± 7.30

713.0 ± 18.67*

658.0 ± 13.24&

733.0 ± 28.21

675.9 ± 33.22

VEGF

657.8 ± 9.40

157.1 ± 16.50*

205.7 ± 7.02&

144.3 ± 41.34

187.8 ± 26.88

  1. * p < 0.05, compared to control group; & p < 0.05, compared to MELAS group; p < 0.05, compared to Pep-1-Mito group. Interleukin (IL)-1β, -7, -8, -12; Granulocyte-macrophage colony-stimulating factor (GM-CSF); Vascular endothelial growth factor (VEGF). All pooled data represent mean ± SD n = 3.
Back to article page